Study of Eye Movements (EYE) as Early Markers of Brain Dysfunction (BRAIN) in Parkinson's Disease (PARK)
NCT ID: NCT04212637
Last Updated: 2020-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2021-01-31
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Volunteers
MRI exam
MRI
Examine BOLD activity in relation to eye movements measures
Parkinson patient
MRI exam
MRI
Examine BOLD activity in relation to eye movements measures
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
Examine BOLD activity in relation to eye movements measures
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Affiliation to a social security scheme (copy of the vital card in support)
* Signed informed consent
* Medical examination according to the participation in the MRI examination
* MMSE score\> 23/30
For Parkinson patient:
* Diagnosis of Parkinson's disease
* Presence of asymmetric bradykinesia and rest tremor and / or stiffness
* Hoehn \& Yahr Stadium I-II / V
Exclusion Criteria
* Protected Major (Persons mentioned in Articles L1121-5,6 and 8 of the public health code)
* Significant hearing or motor impairment
* Past or present neuropsychiatric pathology (except benign epilepsy)
* Taking narcotics and / or drugs for neurocognitive purposes
* Existence of a severe condition in general (cardiac, respiratory, hematological, renal, hepatic, cancerous)
* Any other neurodegenerative pathology or treatment that may affect the oculomotor control
For Parkinson patient:
* Treatment for Parkinson's disease (except the inhibitors of monoaminoxidase B or MAO-B, such as selegiline and rasagiline).
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Laboratoire de Psychologie et NeuroCognition
OTHER
University Hospital, Grenoble
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Grenoble-Alpes
Grenoble, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Tiphaine Montagnon
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38RC18.214
Identifier Type: -
Identifier Source: org_study_id